Speciality Medicines share price today, results and news
Speciality Medicines closed at ₹153.00 on 17 Nov 2026, up 0.00% on the day. It is 59.9% below its 52-week high of ₹381.20 and 26.3% above its 52-week low of ₹121.10. Over the past three months the share price has fallen 3.2%.
At a glance
- Previous close
- ₹153.00
- Open
- ₹153.00
- Day’s range
- ₹153.00 – 153.00
- Volume
- 3,000
Last closing price. Updated after each trading day.
Earnings
Speciality Medicines quarterly results and earnings call
Latest results
Upcoming results
SEBI’s listing rules give companies 45 days after a quarter ends to publish results (60 days for the full year). The exact board-meeting date is announced to the stock exchanges beforehand.
Latest earnings call
Companies usually hold the call on the day of their results or the day after, and post the recording and transcript on their website.
Find the latest transcript (opens in a new tab)5 things to know about Speciality Medicines today
- Closed at ₹153.00 on 17 Nov 2026, up 0.00% on the day.
- Trades 59.9% below its 52-week high of ₹381.20 (29 Apr 2026) and 26.3% above its 52-week low of ₹121.10.
- Down 3.2% over three months, against +4.53% for the Nifty 50.
- 3,000 shares traded in the last session, 0.5× the 20-day average.
Share price vs Nifty 50
| Period | SPML | Nifty 50 |
|---|---|---|
| 1 month | −9.97% | +9.68% |
| 3 months | −3.16% | +4.53% |
| Share price (₹) | Q4 FY26 | Q1 FY27 | Q2 FY27 | Q3 FY27 (to date) |
|---|---|---|---|---|
| Closing price | 125.90 | 203.00 | 158.00 | 153.00 |
| Change QoQ | — | +61.24% | −22.17% | −3.16% |
| High | 129.50 | 381.20 | 201.00 | 210.00 |
| Low | 124.00 | 121.10 | 142.15 | 135.00 |
| Share price (₹) | FY26 | FY27 (to date) |
|---|---|---|
| Closing price | 125.90 | 153.00 |
| Change YoY | — | +21.53% |
| High | 129.50 | 381.20 |
| Low | 124.00 | 121.10 |
Share price by quarter and financial year from closing prices. The reported revenue, profit and EPS of Speciality Medicines will replace this table once added from the company’s results.
Technical indicators
Speciality Medicines technical indicators
Calculated from daily closing prices up to 17 Nov 2026. They describe past prices only and are not a forecast.
RSI compares recent gains with recent losses on a 0 to 100 scale. Readings above 70 are commonly described as overbought and below 30 as oversold.
The MACD line is above its 9-day signal line (−1.11). MACD tracks the gap between the 12-day and 26-day exponential averages.
The close is 2.9% above the average closing price of the last 20 trading days.
The close is 1.5% below the average closing price of the last 50 trading days.
The close is 12% of the way from the 52-week low (₹121.10, 6 Apr 2026) to the high (₹381.20, 29 Apr 2026).
3,000 shares traded in the last session, against a 20-day average of 6,200.
FAQ
Questions about Speciality Medicines
What is the share price of Speciality Medicines today?
Speciality Medicines closed at ₹153.00 on 17 Nov 2026, up 0.00% from the previous close of ₹153.00 on the BSE.
What is the 52-week high and low of Speciality Medicines?
In the last 52 weeks Speciality Medicines traded between a low of ₹121.10 on 6 Apr 2026 and a high of ₹381.20 on 29 Apr 2026. The last close is 59.9% below the high.
How has Speciality Medicines stock performed recently?
Based on closing prices up to 17 Nov 2026, Speciality Medicines shares are down 10.0% over one month, down 3.2% over three months.
What is the stock symbol and ISIN of Speciality Medicines?
Speciality Medicines is listed on the BSE under the symbol SPML. Its ISIN is INE0R0M01014.
About this data
- Prices and indicators: last closing prices, updated 18 Nov 2026, 12:08 am IST.
- Headlines: linked to the publisher that reported them. We store only the headline, link and date.
Disclaimer: Marketasset is an information service and is not registered with SEBI as an investment adviser or research analyst. We do not publish our own analysis or ratings of any stock. Prices are the last closing prices, technical indicators are calculated from past prices, headlines link to the original publisher and company figures come from the company’s own published documents. Nothing here is a recommendation to buy, sell or hold any security.